Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8084582 Optimized anti-CD20 monoclonal antibodies having Fc variants

Patent 8084582 was granted and assigned to Xencor on December, 2011 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Bassil I. Dahiyat0

Gregory Alan Lazar0

Omid Vafa0

Date of Patent

December 27, 2011

Patent Application Number

11174287

Date Filed

June 30, 2005

Patent Citations Received

US Patent 12104156 Compositions and methods of treating facioscapulohumeral muscular dystrophy

0

US Patent 11999955 Compositions and methods of treating facioscapulohumeral muscular dystrophy

0

US Patent 12017050 Drug depot delivery system and method

0

0

US Patent 12064483 Nucleic acid-polypeptide compositions and methods of inducing exon skipping

0

US Patent 12071621 Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

0

US Patent 12076519 Drug delivery device and methods having a retaining member

0

US Patent 11712478 Compositions and methods of treating muscle atrophy and myotonic dystrophy

0

...

Patent Primary Examiner

Patent abstract

The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8084582 Optimized anti-CD20 monoclonal antibodies having Fc variants

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool